Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 10Urinary Bladder Neoplasms 7Ureteral Neoplasms 3Muscle Invasive Bladder Urothelial Carcinoma 2Carcinoma, Renal Cell 2Advanced Bladder Cancer 2Urogenital Neoplasms 1Urachal adenocarcinoma 1Salivary Gland Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Peripheral Nervous System Diseases 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer 1Melanoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma, Adenoid Cystic 1

Interventions

pembrolizumab 5Paclitaxel 4Ifosfamide 4Cisplatin 4Nivolumab 3avelumab 2aldesleukin 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Adoptive Transfer 2vinflunine 1toripalimab 1rocakinogene sifuplasmid 1niraparib 1nimotuzumab 1lenvatinib 1enfortumab vedotin 1durvalumab 1dostarlimab 1dacomitinib 1cemiplimab 1cabazitaxel 1Vorinostat 1VGX-3100 1Ultrasonography 1Surveys and Questionnaires 1Sildenafil Citrate 1Sentinel Lymph Node Biopsy 1Psychiatric Rehabilitation 1Psychiatric Nursing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Penile Neoplasms × enfortumab vedotin × Clear all
NCT06104618 2025-12-11

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

Mayo Clinic

Phase 2 Recruiting
28 enrolled
Genitourinary

Penile Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡